Table 5 Multivariable regression analysis of coronary artery stenosis and plaque pattern with MAFLD severity and risk factors.

From: A clinical study of the correlation between metabolic-associated fatty liver disease and coronary plaque pattern

 

Overall plaque

Calcified plaques

Noncalcified plaques

Mixed plaques

Significant stenosis

OR (95% CI) CI)

P

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

CRUDE

 Non–MAFLD

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 MAFLD

1.35

(1.02–1.80)

0.036

1.42

(1.12–1.80)

0.004

1.82 (1.32–2.52)

0.000

1.42 (1.08–1.88)

0.012

1.36 (1.04–1.78)

0.025

Model 1

 Non–MAFLD

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 MAFLD

1.34 (1.00–1.80)

0.049

1.41 (1.10–1.81)

0.005

1.82 (1.31–2.52)

0.000

1.40 (1.06–1.87)

0.017

1.34 (1.01–1.77)

0.037

Model 2

 Non–MAFLD

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 MAFLD

1.21 (0.87–1.69)

0.237

1.36 (1.04–1.79)

0.024

1.72 (1.21–2.46)

0.003

1.63 (1.19–2.24)

0.002

1.23 (0.90–1.67)

0.180

Model 3

 Non–MAFLD

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 MAFLD

1.16

(0.83–1.61)

0.379

1.35 (1.03–1.77)

0.029

1.67 (1.17–2.39)

0.004

1.59 (1.16–2.18)

0.004

1.17 (0.86–1.60)

0.293

Model 4

 Non–MAFLD

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 MAFLD

1.13 (0.80–1.58)

0.474

1.28 (0.97–1.68)

0.079

1.63 (1.13–2.33)

0.008

1.45 (1.06–2.02)

0.020

1.01 (0.74–1.39)

0.922

Model 5

 Non–MAFLD

1 (reference)

1 (reference)

1 (reference)

1 (reference)

1 (reference)

 MAFLD

1.12 (0.80–1.57)

0.511

1.26 (0.96–1.67)

0.101

1.66 (1.16–2.38)

0.006

1.50 (1.08–2.06)

0.014

1.01 (0.74–1.39)

0.937

  1. Model 1: sex, age, smoking.
  2. Model 2: sex, age, smoking, BMI.
  3. Model 3: sex, age, smoking, BMI, hypertension.
  4. Model 4: sex, age, smoking, BMI, hypertension, Type 2 diabetes.
  5. Model 5: sex, age, smoking, BMI, hypertension, Type 2 diabetes, Hyperlipidemia.